公开(公告)号：US20150219670A1

公开(公告)日：2015-08-06

申请号：US14421382

申请日：2013-08-12

Applicant: Randox Laboratories Ltd.

Inventor： Ivan McConnell ,  Stephen Peter Fitzgerald ,  John Lamont ,  Claran Richardson

IPC: G01N33/68 ,  G01N33/70 ,  G01N33/573

CPC classification number: G01N33/6893 ,  C07K14/475 ,  C07K14/8139 ,  C12N9/104 ,  G01N33/573 ,  G01N33/6845 ,  G01N33/70 ,  G01N33/92 ,  G01N2333/47 ,  G01N2333/8139 ,  G01N2333/9108 ,  G01N2333/91188 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/56

Abstract: The present invention provides a method of stratifying a patient suffering from CKD into one of stages 1-3 of CKD, comprising determining the level of the biomarkers FABP1, γ-GT, AST, creatinine and cystatin C in a sample obtained from the patient and comparing the level of FABP1 in the sample to a control value and the levels of γ-GT, AST, creatinine and cystatin C in the sample to a range of control values for each biomarker, wherein an increased level of FABP1 compared to the control value and levels of γ-GT, AST, creatinine and cystatin C within the range of control values for each biomarker indicate that the patient suffers from stage 1 CKD or wherein an increased level of FABP1 compared to the control value, levels of γ-GT and AST within the range of control values for each biomarker, and increased levels of creatinine and cystatin C compared to an upper threshold of the control range for these biomarkers indicate that the patient suffers from stage 2 or stage 3 CKD.

Abstract translation: 本发明提供了将患有CKD的患者分为CKD的1-3期的方法，包括测定从患者获得的样品中生物标志物FABP1，γ-GT，AST，肌酐和半胱氨酸蛋白酶抑制剂C的水平，以及 将样品中FABP1的水平与对照值和样品中的γ-GT，AST，肌酐和半胱氨酸蛋白酶抑制剂C的水平进行比较，对每种生物标志物的对照值范围进行比较，其中FABP1水平与对照值相比增加 并且每个生物标志物的对照值范围内的γ-GT，AST，肌酐和半胱氨酸蛋白酶抑制剂C的水平表明患者患有1期CKD或其中FABP1水平与对照值相比增加，γ-GT水平和 在每个生物标志物的对照值范围内的AST和与这些生物标志物的对照范围的上限阈值相比，肌酐和半胱氨酸蛋白酶抑制剂C的水平升高表明患者患有2期或3期CKD。

公开(公告)号：US10444248B2

公开(公告)日：2019-10-15

申请号：US14421382

申请日：2013-08-12

Applicant: Randox Laboratories Ltd.

Inventor： Ivan McConnell ,  Stephen Peter Fitzgerald ,  John Lamont ,  Claran Richardson

IPC: G01N33/48 ,  G01N33/68 ,  C12N9/10 ,  G01N33/70 ,  G01N33/92 ,  C07K14/81 ,  C07K14/475 ,  G01N33/573

Abstract: The present invention provides a method of stratifying a patient suffering from CKD into one of stages 1-3 of CKD, comprising determining the level of the biomarkers FABP1, γ-GT, AST, creatinine and cystatin C in a sample obtained from the patient and comparing the level of FABP1 in the sample to a control value and the levels of γ-GT, AST, creatinine and cystatin C in the sample to a range of control values for each biomarker, wherein an increased level of FABP1 compared to the control value and levels of γ-GT, AST, creatinine and cystatin C within the range of control values for each biomarker indicate that the patient suffers from stage 1 CKD or wherein an increased level of FABP1 compared to the control value, levels of γ-GT and AST within the range of control values for each biomarker, and increased levels of creatinine and cystatin C compared to an upper threshold of the control range for these biomarkers indicate that the patient suffers from stage 2 or stage 3 CKD.